

March 2020

## **Kyowa Kirin Statement- Responding COVID-19 Situation**

As Kyowa Kirin continues closely monitoring the coronavirus situation, our primary concern is the health and safety of our employees in the whole Kyowa Kirin Group, as well as that of the healthcare professionals and patients we serve. Also our team is working hard to ensure the stable supply of our drugs to patients. Although we do not anticipate supply chain disruptions at this time, we will continue monitoring the situation closely.

For business continuity, Kyowa Kirin has been implementing the following policies and measures globally while being mindful of the policies put in place by governments, organizations and institutions:

- Restrict general business travel
- Encourage working from home, if available
- Distribute guidance on how our associates and employees can protect themselves against coronavirus infection
- Take various measures especially at our manufacturing sites to mitigate potential risks for drug supply disruption
- Provide our active pharmaceutical ingredients to research institutions in Japan for candidate drug screening

Kyowa Kirin is taking all the necessary steps to protect its associates, patients and products as the situation evolves.

### **About Kyowa Kirin**

Kyowa Kirin commits to innovative drug discovery driven by state-of-the-art technologies. The company focuses on discovering and creating new value through advances in four therapeutic areas: nephrology, oncology, immunology/allergy and neurology. Under the Kyowa Kirin brand, employees from 40 group companies across North America, EMEA and Asia/Oceania unite to champion the interests of patients and their caregivers in areas of unmet medical need. You can learn more about the business of Kyowa Kirin at <https://www.kyowakirin.com/>.